News & Updates
Filter by Specialty:
Continuing enzalutamide after progression improves PFS in mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.
Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022
Use of alternative medicine not uncommon in melanoma patients
About one in four cutaneous melanoma patients use at least one type of complementary and alternative medicine (CAM), of which herbs and turmeric are the most popular, reveals a prospective study from a tertiary cancer centre in Turkey.
Use of alternative medicine not uncommon in melanoma patients
09 Mar 2022
Whole-exome sequencing enhances diagnosis in young CRC patients
Whole-exome sequencing (WES) can improve diagnosis rates in young colorectal cancer (CRC) patients who show no pathogenic variants in mismatch repair (MMR) genes or in the adenomatous polyposis coli (APC) gene, reports a recent study.
Whole-exome sequencing enhances diagnosis in young CRC patients
09 Mar 2022
Neoplastic progression to pancreatic cancer slips by imaging surveillance
Imaging-based surveillance techniques may miss hallmarks of progression in high-risk individuals presenting with high-grade dysplasia or pancreatic cancer, suggesting a need for more sensitive tools, a recent study has found.
Neoplastic progression to pancreatic cancer slips by imaging surveillance
08 Mar 2022
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.